<i>Lactobacillus delbrueckii </i>subsp. lactis LDL557, and composition and use thereof

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need to identify a new strain of Lactobacillus bacteria that effectively alleviates inflammation-related disorders, as current anti-inflammatory drugs have limitations and potential severe side effects.

Innovation Solution

The isolated strain of Lactobacillus delbrueckii subsp. lactis LDL557, deposited under accession number DSM 33617, is used in compositions and administered to subjects to alleviate inflammation-related disorders, including allergies, arthritis, and inflammatory bowel disease.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If immunosuppressive drugs or anti-inflammatory drugs are used to treat inflammation-related disorders, then therapeutic effect is achieved, but severe side effects occur

Engineering Contradiction:

Improvetherapeutic effectVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses Lactobacillus delbrueckii subsp. lactis LDL557 as a biological intermediary to modulate the immune system. Instead of directly blocking cytokine signaling with drugs, the probiotic strain acts as a mediator that restores intestinal microflora balance and indirectly regulates immune response, thereby achieving anti-inflammatory effects without the severe side effects of conventional drugs

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The probiotic Lactobacillus delbrueckii subsp. lactis LDL557 enables the body's own immune system to regulate itself by restoring intestinal microflora balance. The strain promotes the body's natural immune regulation mechanisms rather than suppressing immunity externally, allowing the immune system to self-correct inflammatory responses without requiring strong external intervention

Inventive Principle:

Principle #25Self-service

2Object-affected harmful factors

If conventional anti-inflammatory drugs are used, then inflammation is suppressed, but therapeutic satisfaction is insufficient due to side effects

Engineering Contradiction:

Improveinflammation suppressionVSAvoidtherapeutic satisfaction

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent changes the therapeutic parameter from chemical drug intervention to biological probiotic intervention. By using Lactobacillus delbrueckii subsp. lactis LDL557, the treatment approach shifts from direct pharmacological suppression to biological modulation, changing the nature of the therapeutic agent from synthetic drug to living microorganism that provides sustained benefit without drug-related side effects

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS12478650B2<i>Lactobacillus delbrueckii </i>subsp. lactis LDL557, and composition and use thereof

Publication Date: 2025.11.25 SYNBIO TECH INC

AI summary

Disclosed herein is an isolated strain of Lactobacillus delbrueckii subsp. lactis LDL557, which is deposited at Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH under an accession number DSM 33617. Also disclosed herein are a composition including the isolated strain of Lactobacillus delbrueckii subsp. lactis LDL557, and use of the isolated strain of Lactobacillus delbrueckii subsp. lactis LDL557 for alleviating an inflammation-related disorder.